Capecitabine-d11

Capecitabine-d11 is the deuterium labeled Capecitabine. Capecitabine is an oral proagent that is converted to its active metabolite, 5-FU, by thymidine phosphorylase[1][2].

Product Specifications

CAS Number

[1132662-08-8]

UNSPSC

12352005

Hazard Statement

H341, H350, H360, H402

Target

Apoptosis; DNA/RNA Synthesis; Isotope-Labeled Compounds; Nucleoside Antimetabolite/Analog

Type

Isotope-Labeled Compounds

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Purity

Solubility

DMSO : 250 mg/mL (ultrasonic; warming)

Smiles

C[C@@H]1[C@H]([C@H]([C@H](N2C(N=C(C(F)=C2)NC(OC([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])[2H])=O)=O)O1)O)O

Molecular Formula

C15H11D11FN3O6

Molecular Weight

370.42

Precautions

H341, H350, H360, H402

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]PharmD CM, et al. Capecitabine: A review. Clinical Therapeutics. 2005 Jan; 27 (1) : 23-44.|[3]Guichard SM, et al. Gene expression predicts differential capecitabine metabolism, impacting on both pharmacokinetics and antitumour activity. Eur J Cancer. 2008 Jan;44 (2) :310-7.